Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


A Phase 1 Dose Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.

Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, Madan RA, Marte JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL.

Clin Cancer Res. 2019 May 20. pii: clincanres.0183.2019. doi: 10.1158/1078-0432.CCR-19-0183. [Epub ahead of print]


Yeast Species in the Oral Cavities of Older People: A Comparison between People Living in Their Own Homes and Those in Rest Homes.

Thiyahuddin NM, Lamping E, Rich AM, Cannon RD.

J Fungi (Basel). 2019 Apr 12;5(2). pii: E30. doi: 10.3390/jof5020030.


FK506 Resistance of Saccharomyces cerevisiae Pdr5 and Candida albicans Cdr1 Involves Mutations in the Transmembrane Domains and Extracellular Loops.

Tanabe K, Bonus M, Tomiyama S, Miyoshi K, Nagi M, Niimi K, Chindamporn A, Gohlke H, Schmitt L, Cannon RD, Niimi M, Lamping E.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01146-18. doi: 10.1128/AAC.01146-18. Print 2019 Jan.


First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.

Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL.

Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21.


Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.

Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.


Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL.

Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31.


Role of Ectopic Gene Conversion in the Evolution of a Candida krusei Pleiotropic Drug Resistance Transporter Family.

Lamping E, Zhu JY, Niimi M, Cannon RD.

Genetics. 2017 Apr;205(4):1619-1639. doi: 10.1534/genetics.116.194811. Epub 2017 Feb 3.


Synthetic Organotellurium Compounds Sensitize Drug-Resistant Candida albicans Clinical Isolates to Fluconazole.

Reis de Sá LF, Toledo FT, Gonçalves AC, Sousa BA, Dos Santos AA, Brasil PF, Duarte da Silva VA, Tessis AC, Ramos JA, Carvalho MA, Lamping E, Ferreira-Pereira A.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01231-16. doi: 10.1128/AAC.01231-16. Print 2017 Jan.


Identification and characterization of Candida utilis multidrug efflux transporter CuCdr1p.

Watanasrisin W, Iwatani S, Oura T, Tomita Y, Ikushima S, Chindamporn A, Niimi M, Niimi K, Lamping E, Cannon RD, Kajiwara S.

FEMS Yeast Res. 2016 Jun;16(4). pii: fow042. doi: 10.1093/femsyr/fow042. Epub 2016 May 1.


Identification and functional characterization of Penicillium marneffei pleiotropic drug resistance transporters ABC1 and ABC2.

Panapruksachat S, Iwatani S, Oura T, Vanittanakom N, Chindamporn A, Niimi K, Niimi M, Lamping E, Cannon RD, Kajiwara S.

Med Mycol. 2016 Jul 1;54(5):478-91. doi: 10.1093/mmy/myv117. Epub 2016 Jan 17.


Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Usmani SZ, Choyke PL, Kurdziel K, Landgren O.

Leuk Lymphoma. 2016 May;57(5):1114-21. doi: 10.3109/10428194.2015.1090572. Epub 2016 Apr 7.


Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5.

Keniya MV, Holmes AR, Niimi M, Lamping E, Gillet JP, Gottesman MM, Cannon RD.

Mol Pharm. 2014 Oct 6;11(10):3452-62. doi: 10.1021/mp500230b. Epub 2014 Aug 22.


Small, synthetic, GC-rich mRNA stem-loop modules 5' proximal to the AUG start-codon predictably tune gene expression in yeast.

Lamping E, Niimi M, Cannon RD.

Microb Cell Fact. 2013 Jul 29;12:74. doi: 10.1186/1475-2859-12-74.


Specific interactions between the Candida albicans ABC transporter Cdr1p ectodomain and a D-octapeptide derivative inhibitor.

Niimi K, Harding DR, Holmes AR, Lamping E, Niimi M, Tyndall JD, Cannon RD, Monk BC.

Mol Microbiol. 2012 Aug;85(4):747-67. doi: 10.1111/j.1365-2958.2012.08140.x. Epub 2012 Jul 13.


The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.

Holmes AR, Keniya MV, Ivnitski-Steele I, Monk BC, Lamping E, Sklar LA, Cannon RD.

Antimicrob Agents Chemother. 2012 Mar;56(3):1508-15. doi: 10.1128/AAC.05706-11. Epub 2011 Dec 27.


Chimeras of Candida albicans Cdr1p and Cdr2p reveal features of pleiotropic drug resistance transporter structure and function.

Tanabe K, Lamping E, Nagi M, Okawada A, Holmes AR, Miyazaki Y, Cannon RD, Monk BC, Niimi M.

Mol Microbiol. 2011 Oct;82(2):416-33. doi: 10.1111/j.1365-2958.2011.07820.x. Epub 2011 Sep 19.


Use of a yeast-based membrane protein expression technology to overexpress drug resistance efflux pumps.

Lamping E, Cannon RD.

Methods Mol Biol. 2010;666:219-50. doi: 10.1007/978-1-60761-820-1_15.


Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.

Niimi K, Monk BC, Hirai A, Hatakenaka K, Umeyama T, Lamping E, Maki K, Tanabe K, Kamimura T, Ikeda F, Uehara Y, Kano R, Hasegawa A, Cannon RD, Niimi M.

J Antimicrob Chemother. 2010 May;65(5):842-52. doi: 10.1093/jac/dkq073. Epub 2010 Mar 16.


Fungal PDR transporters: Phylogeny, topology, motifs and function.

Lamping E, Baret PV, Holmes AR, Monk BC, Goffeau A, Cannon RD.

Fungal Genet Biol. 2010 Feb;47(2):127-42. doi: 10.1016/j.fgb.2009.10.007. Epub 2009 Oct 24. Review.


Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p.

Ivnitski-Steele I, Holmes AR, Lamping E, Monk BC, Cannon RD, Sklar LA.

Anal Biochem. 2009 Nov 1;394(1):87-91. doi: 10.1016/j.ab.2009.07.001. Epub 2009 Jul 3.


Efflux-mediated antifungal drug resistance.

Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC.

Clin Microbiol Rev. 2009 Apr;22(2):291-321, Table of Contents. doi: 10.1128/CMR.00051-08. Review.


Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.

Lamping E, Ranchod A, Nakamura K, Tyndall JD, Niimi K, Holmes AR, Niimi M, Cannon RD.

Antimicrob Agents Chemother. 2009 Feb;53(2):354-69. doi: 10.1128/AAC.01095-08. Epub 2008 Nov 17.


ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.

Holmes AR, Lin YH, Niimi K, Lamping E, Keniya M, Niimi M, Tanabe K, Monk BC, Cannon RD.

Antimicrob Agents Chemother. 2008 Nov;52(11):3851-62. doi: 10.1128/AAC.00463-08. Epub 2008 Aug 18.


Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium.

Tanabe K, Lamping E, Adachi K, Takano Y, Kawabata K, Shizuri Y, Niimi M, Uehara Y.

Biochem Biophys Res Commun. 2007 Dec 28;364(4):990-5. Epub 2007 Oct 29.


Candida albicans drug resistance another way to cope with stress.

Cannon RD, Lamping E, Holmes AR, Niimi K, Tanabe K, Niimi M, Monk BC.

Microbiology. 2007 Oct;153(Pt 10):3211-7. Review.


Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae.

Lamping E, Monk BC, Niimi K, Holmes AR, Tsao S, Tanabe K, Niimi M, Uehara Y, Cannon RD.

Eukaryot Cell. 2007 Jul;6(7):1150-65. Epub 2007 May 18.


Amino acid residues affecting drug pump function in Candida albicans--C. albicans drug pump function.

Holmes AR, Tsao S, Lamping E, Niimi K, Monk BC, Tanabe K, Niimi M, Cannon RD.

Nihon Ishinkin Gakkai Zasshi. 2006;47(4):275-81. Review.


Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2.

Holmes AR, Tsao S, Ong SW, Lamping E, Niimi K, Monk BC, Niimi M, Kaneko A, Holland BR, Schmid J, Cannon RD.

Mol Microbiol. 2006 Oct;62(1):170-86. Epub 2006 Aug 30.


Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.

Niimi K, Maki K, Ikeda F, Holmes AR, Lamping E, Niimi M, Monk BC, Cannon RD.

Antimicrob Agents Chemother. 2006 Apr;50(4):1148-55.


[ABC transporters of pathogenic fungi: recent advances in functional analyses].

Niimi M, Tanabe K, Wada S, Yamazaki A, Uehara Y, Niimi K, Lamping E, Holmes AR, Monk BC, Cannon RD.

Nihon Ishinkin Gakkai Zasshi. 2005;46(4):249-60. Review. Japanese.


Characterization of the Saccharomyces cerevisiae sec6-4 mutation and tools to create S. cerevisiae strains containing the sec6-4 allele.

Lamping E, Tanabe K, Niimi M, Uehara Y, Monk BC, Cannon RD.

Gene. 2005 Nov 21;361:57-66. Epub 2005 Sep 26.


Functional analysis of fungal drug efflux transporters by heterologous expression in Saccharomyces cerevisiae.

Niimi M, Wada S, Tanabe K, Kaneko A, Takano Y, Umeyama T, Hanaoka N, Uehara Y, Lamping E, Niimi K, Tsao S, Holmes AR, Monk BC, Cannon RD.

Jpn J Infect Dis. 2005 Feb;58(1):1-7. Review.


Phosphorylation of candida glabrata ATP-binding cassette transporter Cdr1p regulates drug efflux activity and ATPase stability.

Wada S, Tanabe K, Yamazaki A, Niimi M, Uehara Y, Niimi K, Lamping E, Cannon RD, Monk BC.

J Biol Chem. 2005 Jan 7;280(1):94-103. Epub 2004 Oct 21.


Mas37p, a novel receptor subunit for protein import into mitochondria.

Gratzer S, Lithgow T, Bauer RE, Lamping E, Paltauf F, Kohlwein SD, Haucke V, Junne T, Schatz G, Horst M.

J Cell Biol. 1995 Apr;129(1):25-34.


Repression of the L-asparaginase gene during nodule development in Lupinus angustifolius.

Vincze E, Reeves JM, Lamping E, Farnden KJ, Reynolds PH.

Plant Mol Biol. 1994 Oct;26(1):303-11.


Coordinate regulation of phosphatidylserine decarboxylase in Saccharomyces cerevisiae.

Lamping E, Kohlwein SD, Henry SA, Paltauf F.

J Bacteriol. 1991 Oct;173(20):6432-7.

Supplemental Content

Loading ...
Support Center